Susan Galbraith: AstraZeneca has announced an agreement to acquire EsoBiotec
Susan Galbraith, Executive Vice President in Oncology R&D at AstraZeneca, shared a post on LinkedIn:
“Thrilled to share that AstraZeneca has announced an agreement to acquire EsoBiotec, a clinical-stage biotech company pioneering in vivo cell therapies.
EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and destroy tumour cells for cancer treatment or autoreactive cells for potential use in immune-mediated diseases.
This approach enables cell therapies to be administered in minutes through a simple IV injection and without the need for immune cell depletion.
We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising in vivo platform, which we believe has the potential to transform cell therapy and enable us to scale these innovative treatments so that many more patients can access them.
The proposed acquisition marks a major step forward in realising our ambition to harness the full potential of cell therapy.”
More posts featuring Susan Galbraith.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023